Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Metastatic Melanoma with mTOR Mutations
NCT01960829Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in melanoma, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
everolimus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01960829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960829.